Pioneering novel targeted cell therapies for cancer



CAR-T therapy has emerged as a promising new treatment approach for hematologic (blood-borne) cancers. This approach works by modifying the body’s own immune cells (T-cells) so that they recognize and kill cancer cells by targeting markers (antigens) on the cells’ surface. To date, successful CAR-T therapy has been largely limited to patients with advanced B-cell malignancies. In these patients, CAR-T cells target markers that are present on all B-cells, both healthy and cancerous. While the body can safely function without B-cells, using CAR-T therapy to treat other cancers—which would involve targeting cells necessary for survival—remains elusive. Furthermore, CAR-T therapy has shown more limited results in treating solid tumors. Vor Biopharma is developing a new approach to CAR-T therapy to broaden its applicability in other cancers, particularly those with limited therapeutic options, by overcoming key barriers that limit current modalities. Vor is excited to have the support of a world-class team of immunologists and oncologists to develop its pipeline of novel immunotherapies.

Our Team

Joseph Bolen, Ph.D.
Acting Chief Scientific Officer and Member of the Scientific Advisory Board

Dr. Bolen is also Chief Scientific Officer at PureTech Health. Dr. Bolen has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research. He began ...

Sanjiv Sam Gambhir, M.D., Ph.D.
Member of the scientific advisory board

Dr. Gambhir is a Professor of Radiology, Materials Science & Engineering, and Bioengineering at Stanford University, where he is also Chair of the Department of Radiology and Director of the Molecular Imaging Program. He is the recipient of over $90M in NIH ...

Dan Littman, M.D., Ph.D.
member of the scientific advisory board

Dr. Littman is a Howard Hughes Medical Institute Investigator and the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology at the New York University (NYU) School of Medicine. Dr. Littman has made ...


Siddhartha Mukherjee, M.D., D.Phil
Member of the Scientific Advisory Board

Dr. Mukherjee is an Assistant Professor of Medicine at Columbia University and a Staff Physician at Columbia University Medical Center. Dr. Mukherjee is the author of The Emperor of All Maladies: A Biography of Cancer, winner of the 2011 Pulitzer Prize in ...

Derrick J. Rossi, Ph.D.
member of the scientific advisory board

Dr. Rossi is an Associate Professor in the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University. Dr. Rossi is also an investigator in the Program in Cellular and Molecular Medicine at Boston Children’s ...

Justin Stebbing, Ph.D., F.R.C.P., F.R.C.Path.
Member of the Scientific Advisory Board

Dr. Stebbing is a Professor of Cancer Medicine and Oncology & Consultant Oncologist at Imperial College London and Imperial College Healthcare National Health Service (NHS) Trust. Dr. Stebbing’s research is focused on discovering new ...

David Steinberg
Acting CEO, Co-Founder, and Member of the board of directors

Mr. Steinberg is the Chief Innovation Officer at PureTech Health. As a member of PureTech Health, Mr. Steinberg has led the development of a number of programs, including Vedanta Biosciences, Entrega Biosciences, and Commense Health. He also served ...


Aleks Radovic-Moreno, Ph.D.

Dr. Radovic-Moreno is Vice President at PureTech Health. He was previously a Research Scientist at the biotech startup AuraSense Therapeutics, where he was a lead inventor of the company's core immunotherapy platform. Dr. Radovic-Moreno completed ...






SUITE 6102
BOSTON, MA 02116